Literature DB >> 15761609

Hepatitis C virus genotypes in blood donors from the Federal District, Central Brazil.

Regina M S Amorim1, Claudiner P Oliveira, Patrícia S Wyant, Daniela M Cerqueira, Geni N L Câmara, Luciano S Flores, Regina M B Martins, Cláudia R F Martins.   

Abstract

The objective of this study was to characterize hepatitis C virus (HCV) genotypes in blood donors from the Federal District, Central Brazil, and to compare HCV screening by serological assays and reverse transcriptase polymerase chain reaction (RT-PCR). Plasma samples from 57 individuals with reactive or indeterminate results in serological anti-HCV screening assays (ELISA or EIA) were tested for HCV RNA by RT-PCR. The results from a confirmatory LIA serological assay were also evaluated. The 5' non-coding region of the HCV genome was amplified from 41 PCR positive samples (71.9%), which were further characterized by nucleotide sequencing analysis. Of these, 60.9% were of HCV genotype 1 and 39.1% of genotype 3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761609     DOI: 10.1590/s0074-02762004000800019

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  2 in total

1.  Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients.

Authors:  Beatris Maria Vidales-Braz; Naylê Maria Oliveira da Silva; Rubens Lobato; Fabiana Nunes Germano; Luiza Dias da Mota; Elvino J G Barros; Ana Maria Barral de Martinez
Journal:  Virol J       Date:  2015-02-03       Impact factor: 4.099

2.  Hepatitis C virus in blood donors, Brazil.

Authors:  Kátia Luz Torres; Adriana Malheiro; Adriana Tateno; Tatiane Amabile de-Lima; Laura Patricia Viana-Maia; João Paulo Diniz-Pimentel; Márcia Poinho Encarnação-de-Morais; Christiane Santana de-Melo-Usui; Flavia de-Oliveira-Braga; Igor Araújo Ferreira-Silva; Felicien Vasquez; José Eduardo-Levi
Journal:  Emerg Infect Dis       Date:  2009-04       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.